Syndax

SpringWorks Therapeutics

This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.

Nuvation Bio

This biopharmaceutical company develops and commercialises targeted oncology therapies for patients with cancers that have unmet medical needs.

Tracon Pharmaceuticals

This biopharmaceutical company develops and commercialises targeted cancer therapeutics for life science partners and patients in the United States.

ArriVent

This biopharmaceutical company develops and commercialises oncology therapeutics, including targeted medicines and antibody-drug conjugates, to treat patients with difficult-to-treat cancers globally.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.

Blueprint Medicines

This biopharmaceutical company develops and commercialises kinase inhibitors for patients with systemic mastocytosis, gastrointestinal stromal tumours and other genomic-driven cancers.

Arcutis Biotherapeutics

This biopharmaceutical company develops and commercialises topical treatments for patients with chronic inflammatory skin diseases such as psoriasis, eczema, and seborrhoeic dermatitis.